Calithera Biosciences, Inc.

172 articles about Calithera Biosciences, Inc.

• Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 02, 2020

  11/2/2020

  Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted three new employees non-qualified stock options to purchase an aggregate of 138,500 shares of Calithera’s common stock, at a per share exercise price of $3.54, the closing trading price on October 30, 2020.

• Calithera Biosciences to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

  10/29/2020

  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s third quarter 2020 financial results will be released on Thursday, November 5, 2020.

• Calithera Biosciences’ CB-280 Arginase Inhibitor Trial in Progress Poster Presented at the North American Cystic Fibrosis 2020 Virtual Conference

  10/7/2020

  Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that a poster detailing the trial design of a Phase 1b study of CB-280, the company’s arginase inhibitor, is being presented today at the North American Cystic Fibrosis (NACFC) 2020 Virtual Conference.

• Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Oct 02, 2020

  10/2/2020

  Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 2,100 shares of Calithera’s common stock, at a per share exercise price of $3.45, the closing trading price on September 30, 2020.

• Calithera Biosciences Initiates KEAPSAKE Randomized Phase 2 Trial of Telaglenastat in Combination with Chemoimmunotherapy to Treat Aggressive Form of Lung Cancer

  9/24/2020

  Study will evaluate safety and efficacy of glutaminase inhibition in combination with standard-of-care treatment in front-line setting among patients with non-small cell lung cancer and a mutation in the KEAP1/NRF2pathway

• Calithera to Participate in Multiple Upcoming Investor Conferences - Sep 04, 2020

  9/4/2020

  Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that the company will participate in four upcoming virtual healthcare investor conferences.

• Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sep 02, 2020

  9/2/2020

  Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 8,000 shares of Calithera’s common stock, at a per share exercise price of $4.03 the closing trading price on August 31, 2020.

• Calithera Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights

  8/10/2020

  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel, small-molecule drugs for the treatment of cancer and other life-threatening diseases, announced today its financial results for the second quarter ended June 30, 2020.

• Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Aug 03, 2020

  8/3/2020

  Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 30,000 shares of Calithera’s common stock, at a per share exercise price of $4.70, the closing trading price on July 31, 2020.

• Calithera Biosciences to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020

  7/28/2020

  Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that the Company’s second quarter 2020 financial results will be released on Monday, August 10, 2020.

• Calithera Biosciences Appoints Scott Garland to Board of DirectorsFormer Portola Pharmaceuticals President and Chief Executive Officer Brings Extensive Executive Leadership and Commercial Oncology Experience

  7/14/2020

  Calithera Biosciences announced the appointment of Scott Garland to its board of directors.

• Calithera Biosciences Initiates Phase 1b Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis

  7/13/2020

  Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that it has dosed the first patients in its Phase 1b clinical trial of the arginase inhibitor CB-280 in adult patients with cystic fibrosis and chronic airway infection.

• Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 02, 2020

  7/2/2020

  Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted two new employees a non-qualified stock option to purchase an aggregate of 14,500 shares of Calithera’s common stock, at a per share exercise price of $5.28, the closing trading price on June 30, 2020.

• Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 02, 2020

  6/2/2020

  Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted two new employees a non-qualified stock option to purchase an aggregate of 15,200 shares of Calithera’s common stock, at a per share exercise price of $5.82, the closing trading price on May 29, 2020.

• Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at ASCO20 Virtual Annual Meeting

  5/29/2020

  KEAPSAKE is a planned Phase 2 randomized trial exploring telaglenastat with standard of care in first-line treatment of patients with lung cancer with KEAP1/NRF2 mutations

• Calithera to Present at the Jefferies 2020 Virtual Healthcare Conference

  5/27/2020

  Calithera Biosciences, Inc. announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the Jefferies Virtual Healthcare Conference at 8:00 a.m. ET on Thursday, June 4, 2020.

• Calithera Biosciences Reports First Quarter 2020 Financial Results and Recent Highlights

  5/7/2020

  Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel, small-molecule drugs for the treatment of cancer and other life-threatening diseases, announced its financial results for the first quarter ended March 31, 2020.

• Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 06, 2020

  5/6/2020

  Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 3,500 shares of Calithera’s common stock, at a per share exercise price of $6.13, the closing trading price on April 30, 2020.

• Calithera Biosciences to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020

  5/1/2020

  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s first quarter 2020 financial results will be released on Thursday, May 7, 2020.

• Calithera Biosciences Announces Telaglenastat KEAPSAKE Trial in Progress Abstract Accepted for Presentation at ASCO20 Virtual Annual Meeting

  4/30/2020

  KEAPSAKE is a Phase 2 randomized trial exploring telaglenastat with standard of care in first-line treatment of patients with lung cancer with KEAP1/NRF2 mutations